A complete remission rate of 36.9 percent versus 5.7 percent is not a marginal clinical difference. That 31-point gap, drawn from the phase III MAJESTY trial comparing obinutuzumab against tacrolimus in adults with primary membranous nephropathy, is the data behind the FDA’s Priority Review designation for Roche’s Gazyva/Gazyvaro, with a decision expected by November 2026. The disease mechanism matters here: in pMN, the immune system attacks the kidney’s glomeruli, protein leaks into the urine, and without sufficient remission, up to 30 percent of patients progress to kidney failure over a decade. The current standard of care has long been off-label immunosuppression, including calcineurin inhibitors like tacrolimus, because approved options for pMN specifically remain essentially absent from the regulatory landscape.
The MAJESTY trial enrolled 142 adults randomized 1:1, and the primary endpoint was the proportion achieving complete remission at week 104, defined by KDIGO criteria as proteinuria below 0.3 g/day alongside normal serum creatinine and albumin. Obinutuzumab hit superiority on that endpoint and on two key secondary endpoints: overall remission and complete remission at the earlier 76-week mark. Safety tracked with the drug’s established profile, no new signals. The results appeared as a late-breaking oral at the European Renal Association Congress in June and published simultaneously in the New England Journal of Medicine, a combination that tends to accelerate regulatory confidence rather than create it after the fact.
What makes this Priority Review strategically significant is its position within a pattern. MAJESTY is the fourth positive phase III trial for obinutuzumab in immune-mediated disease, following REGENCY in lupus nephritis, ALLEGORY in SLE, and INShore in idiopathic nephrotic syndrome, the last of which also received Priority Review and Breakthrough Therapy Designation just two months ago in May 2026. The drug already carries Breakthrough Therapy Designation in pMN, granted in April 2026. Roche is simultaneously filing MAJESTY data with the EMA, and the POSTERITY study is running in pediatric lupus nephritis. Obinutuzumab’s anti-CD20 mechanism, engineered for enhanced B-cell depletion including tissue-resident populations, is the mechanistic thread connecting each of these indications.
The single marker to track before November is whether the FDA’s review surfaces any questions about the open-label MAJESTY design. Blinding was not feasible given the infusion-versus-oral comparison, but open-label trials in remission-based endpoints carry labeling risk, and how the agency frames the complete remission rate in the prescribing information will directly shape how nephrologists and payers interpret that 36.9 percent figure in practice.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
